MOREPENLAB · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 27/100 — Quality 34 · Valuation 17 · Momentum 28
| Share price | ₹58.23 |
| Market cap | ₹3,355 Cr |
| P/E ratio | 35.4 |
| P/B ratio | 2.8 |
| ROE | 86.6% |
| ROCE | 9.4% |
| Dividend yield | 0.33% |
| Book value | ₹22.17 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹1,806 Cr | ₹96 Cr | 7.0% |
| 2025 | ₹1,812 Cr | ₹118 Cr | 10.0% |
| 2024 | ₹1,690 Cr | ₹97 Cr | 9.0% |
| 2023 | ₹1,418 Cr | ₹39 Cr | 6.0% |
| 2022 | ₹1,547 Cr | ₹102 Cr | 9.0% |
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-ulcerative, and anti-depressant drugs; and home diagnostic products, such as air purifiers, sphygmomanometers, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors,